Ionis Pharmaceuticals (IONS) Earnings Looks Straightforward as Ongoing Trials Will Present Future Catalysts - RBC Capital

February 25, 2021 7:07 AM EST Send to a Friend
RBC Capital analyst Luca Issi reiterated an Outperform rating and $76.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS) after the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login